In an interview recorded during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discussed results from a phase 2 trial where researchers from the Fondazione Italiana Linfomi found that the addition of intermediate-dose of cytarabine to the first line treatment of rituximab and bendamustine led to a 91% response rate in elderly people with mantle cell lymphoma. This chemotherapy combination is known as RBAC500.
New Developments in Lymphoma 